Neurometa Therapeutics
PrivateLast Round
Accelerator
May 21, 2025
Total Funding Raised
$2.46M
Company Overview
Neurometa Therapeutics operates in Healthcare & Life Sciences and is based in Lund. Its latest recorded funding round was an Accelerator round in May 2025.
Neurometa Therapeutics is a biotechnology company developing a novel neurometabolic approach to treating neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Defense Tech
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurometa Therapeutics Comparables
Compare Neurometa Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NRG Therapeutics | 81% | |
| T3D Therapeutics, Inc. | 77% | |
| Clene | 75% |
For institutional investors. Book with your work email.
Neurometa Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | May 21, 2025 | ||||
| Grant | Dec 10, 2022 | ||||
| Seed | Sep 22, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neurometa Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Department of War | Grant |
| BioInnovation Institute | Seed |
| SmiLe Venture Hub | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 14, 2025
Grew 60% QoQ, from 10 to 16 employees.
- Oct 15, 2025
Grew 45% QoQ, from 11 to 16 employees.
For institutional investors. Book with your work email.
Neurometa Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neurometa Therapeutics's valuation, stock price, and market status.
Is Neurometa Therapeutics a public or private company?
Neurometa Therapeutics is a private company.
What is the current stock price of Neurometa Therapeutics?
Neurometa Therapeutics is a private company, so its shares have no public market price. Caplight tracks Neurometa Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neurometa Therapeutics worth (valuation)?
Valuation information for Neurometa Therapeutics is not publicly available.
Can I buy Neurometa Therapeutics stock?
Neurometa Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neurometa Therapeutics's last funding round?
Neurometa Therapeutics's most recent funding round was Accelerator on May 21, 2025.
Who are the main investors in Neurometa Therapeutics?
Key investors in Neurometa Therapeutics include BioInnovation Institute.
Will Neurometa Therapeutics IPO soon?
No public IPO plans have been announced for Neurometa Therapeutics.
How can I track Neurometa Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Neurometa Therapeutics's shares on secondary markets.